X4 Pharmaceuticals, Inc
X4 Pharmaceuticals (XFOR) secured a $150M senior debt facility with K2 HealthVentures, replacing a prior loan. $80M was used to repay existing debt, with $70M available. Funds support corporate activities and potential mavorixafor launch. X4 expects Phase 3 trial enrollment completion by year-end 2026 and topline data in H1 2028.
X4 Pharmaceuticals (XFOR) issued 80,000 stock options to new employees under its 2019 Inducement Equity Incentive Plan. The options have a 10-year term, a $2.90 exercise price, and vest over 4 years. The company focuses on rare hematology diseases and is conducting a Phase 3 trial for mavorixafor, its lead drug.
X4 Pharmaceuticals (XFOR) reported a positive FDA Type C meeting outcome, reducing the 4WARD Phase 3 trial sample size from 176 to 126 participants. The FDA agreed the revised size maintains adequate power. The company expects enrollment completion by year-end 2026 and topline data in H1 2028. Mavorixafor targets chronic neutropenia, a rare disease with limited therapy options.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning XFOR (X4 Pharmaceuticals, Inc). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent XFOR coverage spans corporate actions, insider activity and financial news.
In the last 30 days, XFOR insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($34K). The most active reporter was KIRSKE DAVID, Chief Financial Officer, with 1 filing.
The financing strengthens X4's balance sheet and reduces refinancing risk, likely supporting the stock price.
The grant creates modest dilution and may exert slight downward pressure on the share price.
The FDA alignment reduces trial cost and timeline, likely improving X4's valuation outlook.
An insider open-market sale reduces insider exposure but is not, by itself, a fundamental catalyst.
This is a disclosed insider open-market sale, which can modestly affect sentiment but is not itself a fundamental change.
AlphAI scores every news story that mentions XFOR with an AI model for sentiment and relevance, and aggregates insider trades from X4 Pharmaceuticals, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
X4 Pharmaceuticals (XFOR) secured a $150M senior debt facility with K2 HealthVentures, replacing a prior loan. $80M was used to repay existing debt, with $70M available. Funds support corporate activities and potential mavorixafor launch. X4 expects Phase 3 trial enrollment completion by year-end 2026 and topline data in H1 2028.
2 min readX4 Pharmaceuticals (XFOR) issued 80,000 stock options to new employees under its 2019 Inducement Equity Incentive Plan. The options have a 10-year term, a $2.90 exercise price, and vest over 4 years. The company focuses on rare hematology diseases and is conducting a Phase 3 trial for mavorixafor, its lead drug.
1 min readX4 Pharmaceuticals (XFOR) reported a positive FDA Type C meeting outcome, reducing the 4WARD Phase 3 trial sample size from 176 to 126 participants. The FDA agreed the revised size maintains adequate power. The company expects enrollment completion by year-end 2026 and topline data in H1 2028. Mavorixafor targets chronic neutropenia, a rare disease with limited therapy options.
2 min readVolpone John (President) sold 24,576 shares of X4 Pharmaceuticals, Inc (XFOR) at $4.44 ($0.11M total) on 2026-08-12.
1 min readCraig Adam R (Executive Chairman) sold 47,436 shares of X4 Pharmaceuticals, Inc (XFOR) at $4.44 ($0.21M total) on 2026-08-12.
2 min readX4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly results with revenue of $8.8m, 264% above expectations, and a statutory loss of $0.13 per share. Analysts updated forecasts, raising 2026 revenue consensus to $16.2m and cutting expected loss per share to $0.65. The average price target increased 57% to $11.60.
7 min readX4 Pharmaceuticals (Nasdaq: XFOR) said it issued inducement equity awards effective July 6, 2026 to new employees under its 2019 Inducement Equity Incentive Plan. The grants total options for 750,000 shares, with a $4.03 exercise price, 10-year term, and 4-year vesting (25% after 12 months, then monthly).
2 min readX4 Pharmaceuticals, Inc (XFOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. xfor-20260630 0001501697 FALSE 0001501697 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readX4 Pharmaceuticals (Nasdaq: XFOR) said it appointed Kelly Gold to its board effective July 1, 2026. She will be an independent director and Audit Committee member. X4 noted she is CFO of CAMP4 Therapeutics (Nasdaq: CAMP) and has prior Biogen experience. The company said it aims to advance mavorixafor toward potential approval and commercialization.
2 min readX4 Pharmaceuticals (Nasdaq: XFOR) said it issued inducement equity awards effective May 29, 2026 to new employees under its 2019 Inducement Equity Incentive Plan. The awards total options for 160,000 shares, with a $4.31 exercise price and a 10-year term. Options vest over four years, subject to continued employment, per Nasdaq Rule 5635(c)(4).
3 min read
